Beijing Luzhu Biotechnology Co Ltd
02480
Company Profile
Business description
Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. The Group’s product pipeline consisted of three clinical-stage product candidates, including its Core Product, LZ901, and six pre-clinical-stage product candidates.
Contact
No. 3 Guangtong Street
Industrial Development Zone, Zhangjiawan Tongzhou District
Beijing
CHNT: +86 1061568561
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
164
Stocks News & Analysis
stocks
Another incredible quarter from Microsoft
We were wrong when we thought last quarter would be hard to top.
stocks
10 best US dividend aristocrats to buy now—including a surprise outperformer
These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks
Leading ASX players in this field look materially overvalued
We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,930.80 | 68.20 | -0.76% |
| CAC 40 | 7,771.97 | 89.99 | -1.14% |
| DAX 40 | 24,065.47 | 196.75 | -0.81% |
| Dow JONES (US) | 44,130.98 | 330.30 | -0.74% |
| FTSE 100 | 9,132.81 | 4.13 | -0.05% |
| HKSE | 24,802.94 | 29.61 | 0.12% |
| NASDAQ | 21,122.45 | 7.23 | -0.03% |
| Nikkei 225 | 40,914.66 | 155.16 | -0.38% |
| NZX 50 Index | 12,770.69 | 53.05 | -0.41% |
| S&P 500 | 6,339.39 | 23.51 | -0.37% |
| S&P/ASX 200 | 8,675.00 | 67.80 | -0.78% |
| SSE Composite Index | 3,576.84 | 3.63 | 0.10% |